Molecular Prospection and Bioinformatics Group, Laboratory Keizo Asami of Immunopathology (LIKA), Federal University of Pernambuco (UFPE), Brazil.
Molecular Prospection and Bioinformatics Group, Laboratory Keizo Asami of Immunopathology (LIKA), Federal University of Pernambuco (UFPE), Brazil; Clinical Hospital of Pernambuco - Professor Romero Marques, Federal University of Pernambuco (UFPE), Brazil.
Biomed Pharmacother. 2018 Oct;106:14-34. doi: 10.1016/j.biopha.2018.06.066. Epub 2018 Jun 23.
Breast Cancer is a complex disease characterized by the occurrence of multiple molecular alterations. Currently, some molecular markers are in use for breast cancer diagnostic, prognostic, and predictive purposes. Thus, genetic signatures are available for improving the decision-making. The biomarkers are also essential as therapeutic approaches, but many questions remain due to the lack of efficacy on breast cancer treatment, mainly for triple-negative breast cancer subtype. Since the genetic profile of breast cancer can also be related to different ethnic groups and geographic areas, the reference populations of the genetic assays and clinical trials need to include a broader population beyond the European and North American patients. In this review, we analyzed the current and potential molecular markers that could help to improve the strategies for breast cancer therapy.
乳腺癌是一种复杂的疾病,其特征是发生多种分子改变。目前,一些分子标志物用于乳腺癌的诊断、预后和预测目的。因此,遗传特征可用于改善决策。这些生物标志物也是治疗方法的关键,但由于缺乏对乳腺癌治疗的疗效,主要是三阴性乳腺癌亚型,仍存在许多问题。由于乳腺癌的遗传特征也可能与不同的种族和地理区域有关,因此遗传检测和临床试验的参考人群需要包括超出欧洲和北美患者的更广泛的人群。在这篇综述中,我们分析了目前和潜在的分子标志物,这些标志物可能有助于改善乳腺癌治疗策略。